Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: Prospective trial on 156 eyes throughout 12-month follow-up

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 8, 2009, Pages 1031-1037

  Costagliola, Ciro ^a   Semeraro, Francesco ^b   Cipollone, Ugo ^c   Rinaldi, Michele ^d   de lla Corte, Michele ^d   Romano, Mario R ^a,e  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Ospedale G Vietri   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e Dipartimento di Scienze Animali   (Italy)

Author keywords

Age relatedmacular degeneration; Anti VEGF; Bevacizumab; Choroidal neovascularization

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; SIDE EFFECT; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; THICKNESS; THROMBOEMBOLISM; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INDOCYANINE GREEN; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 67651085336     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1081-y     Document Type: Article

References (26)

1. Fine SL, Berger JW, Maguire MG, Ho AC (2000) Age-related macular degeneration. N Engl J Med 342:483-492, doi: 10.1056/NEJM200002173420707
2. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, doi: 10.1016/ S0092-8674(00)80108-7
3. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A (1998) Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 39:2194-2200
4. Macular Photocoagulation Study Group (1994) Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112:480-488
5. Macular Photocoagulation Study Group (1996) Occult choroidal neovascularization: Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 114:400-412
6. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT (1997) Increased expression of angiogenic factors in age-related maculopathy. Br J Ophthalmol 81:154-162, doi: 10.1136/bjo.81.2.154
7. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, doi: 10.1210/er.18.1.4
8. Aisenbrey S, Ziemssen F, Volker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU (2007) Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:941-948, doi: 10.1007/ s00417-006-0471-7
9. Kim R (2007) Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 55:413-415, doi: 10.4103/ 0301-4738.36473
10. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372, doi: 10.1016/ j.ophtha.2005.11.019
11. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331-335
12. Rinaldi M, Dell'Omo R, Romano MR, Chiosi F, Cipollone U, Costagliola C (2007) Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch Ophthalmol 125:1422-1423, doi: 10.1001/archopht.125.10.1422
13. Costagliola C, Romano MR, Dellomo R, Cipollone U, Polisena P (2007) Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. Am J Ophthalmol 144:449-451, doi: 10.1016/ j.ajo.2007.05.025
14. Chen Y, Wiesmann C, Fuh G et al (1999) Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293:865-881, doi: 10.1006/ jmbi.1999.3192
15. Houck KA, Leung DW, Rowland AM et al (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037
16. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study group (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868-1875, doi: 10.1016/j.ophtha.2007.04.030
17. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:246-252, doi: 10.1016/j.ophtha.2006.10.045
18. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: Subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850-857, doi: 10.1016/j.ajo.2007.08.012
19. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361-372
20. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM (2006) Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26:994-998, doi: 10.1097/01.iae.0000244380.34082.67
21. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27:439-444, doi: 10.1097/IAE.0b013e31804b3e15
22. Azad RV, Khan MA, Chanana B, Azad S (2008) Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol 52:52-56, doi: 10.1007/s10384-007-0496-4
23. Incorvaia C, Campa C, Parmeggiani F, Menzione M, D'Angelo S, Della Corte M, Rinaldi M, Romano M, Dell'omo R, Costagliola C (2008) 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration. Retina 28:289-297, doi: 10.1097/IAE.0b013e31813ffe90
24. Melamud A, Stinnett SA, Fekrat S (2008) Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: Efficacy of three consecutive monthly injections. Am J Ophthalmol 146:91-95, doi: 10.1016/j.ajo.2008.03.014
25. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I (2007) Targeting vascular endothelial growth factor: A promising strategy for treating age-related macular degeneration. Drugs Aging 24:643-662, doi: 10.2165/ 00002512-200724080-00003
26. Raftery J, Clegg A, Jones J, Tan SC, Lotery A (2007) Ranibizumab (Lucentis) versus bevacizumab (Avastin): Modelling cost effectiveness. Br J Ophthalmol 91:1244-1246, doi: 10.1136/bjo.2007.116616